You searched for "rare"

2048 results found

Specialty-driven EMR for paperless clinical environment – insights for an informed choice

Deployment of specialty-driven (or specialty-specific) electronic medical record (EMR) systems across UK ophthalmology units appears to be growing rapidly at the expense of generic, multiuse digital technology packages. Experience further suggests that open source systems can play a significant role...

Anterior segment imaging: a photographer’s view

My name is Rosalyn Painter and I work within the vision science and ophthalmic imaging team at Bristol Eye Hospital, where we cover all aspects of imaging within the hospital, including fluorescein angiograms, fundus photography, optical coherence tomography (OCT), slit-lamp...

The miracle of multi-professional working in modern-day eyecare

"It’s a Tuesday morning, and I’m in the presence of one of the most mind-boggling accomplishments in human history. This thing is so astounding in its complexity and scope, it makes the Panama Canal look like a third grader’s craft...

Prognostic AI for diabetic retinopathy: Towards the first prospective trial in the UK

Artificial intelligence (AI) is frequently described as having the capacity to dramatically change and improve healthcare. One extensively studied application of AI in ophthalmology involves the diagnosis of diabetic retinopathy (DR) or diabetic maculopathy (DM) using retinal imaging. An emerging...

Second major survey calls for people with sight loss to review ideas for innovation of post diagnostic support for blind and partially sighted people

This September the UK’s largest sight loss charity, The Royal National Institute of Blind People (RNIB), is launching the second in a series of major surveys to help map out the future of support for people diagnosed with serious eye...

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

Management of giant retinal tears with vitrectomy and perfluorocarbon liquid postoperatively as a short-term tamponade

The authors report an eight year retrospective case series study of 30 eyes of 29 patients with who underwent a giant retinal tear-related retinal detachment repair. M: F ratio was 23:6. Right to left eye ratio was 16:14. The mean...

Endophthalmitis after intravitreal anti-VEGF injection

The authors report the results of a retrospective multicentre study conducted at 17 retina referral centres to investigate the microbial spectrum of endophthalmitis after anti-VEGF injections. A total of 83 cases of culture-positive endophthalmitis (58.4%) were included. The most frequent...

In conversation with Dr Robert B Nussenblatt

Dr Robert B Nussenblatt is Chief of the Laboratory of Immunology at the National Eye Institute, an eminent ocular immunologist and an expert in clinical research design and conduct. Describe the success or relevance of the SUN project. The Standardization...

The role of aspirin in the treatment of NAION: Benefits and controversies

Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in individuals over 50 with estimated prevalence of 2–10 per 100,000 people, characterised by sudden, unilateral vision loss due to ischaemic injury to the optic nerve head....

What's trending Jun/Jul 2023

A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #whoopigoldberg #presbyopia #bionic Whoopi Goldberg made a name for herself in blockbusters such as the Oscar-winning Ghost and Sister Act. She...

A case of ‘60-day glaucoma’

Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...